Gotham Asset Management LLC purchased a new stake in shares of Teladoc, Inc. (NYSE:TDOC) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 15,348 shares of the health services provider’s stock, valued at approximately $384,000.
Several other institutional investors have also recently modified their holdings of TDOC. Great West Life Assurance Co. Can acquired a new stake in shares of Teladoc during the first quarter valued at about $105,000. US Bancorp DE increased its stake in shares of Teladoc by 10.3% in the first quarter. US Bancorp DE now owns 4,617 shares of the health services provider’s stock valued at $116,000 after buying an additional 433 shares during the period. Legal & General Group Plc increased its position in Teladoc by 66.3% in the first quarter. Legal & General Group Plc now owns 6,137 shares of the health services provider’s stock worth $154,000 after buying an additional 2,446 shares during the last quarter. First Mercantile Trust Co. purchased a new position in Teladoc during the first quarter worth about $175,000. Finally, Blair William & Co. IL purchased a new position in Teladoc during the first quarter worth about $218,000. 93.76% of the stock is currently owned by institutional investors and hedge funds.
Shares of Teladoc, Inc. (NYSE:TDOC) traded down 0.15% during trading on Friday, reaching $34.40. The company’s stock had a trading volume of 430,508 shares. The stock has a 50-day moving average of $34.18 and a 200-day moving average of $25.94. Teladoc, Inc. has a 52-week low of $13.49 and a 52-week high of $36.90. The stock’s market cap is $1.87 billion.
Teladoc (NYSE:TDOC) last posted its earnings results on Monday, May 8th. The health services provider reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.03. Teladoc had a negative net margin of 53.58% and a negative return on equity of 24.73%. The business had revenue of $42.90 million during the quarter, compared to the consensus estimate of $42.22 million. During the same quarter in the previous year, the firm posted ($0.40) EPS. The firm’s revenue was up 59.5% on a year-over-year basis. Analysts predict that Teladoc, Inc. will post ($0.88) earnings per share for the current fiscal year.
A number of research analysts recently issued reports on the company. Piper Jaffray Companies reiterated a “buy” rating and set a $32.00 price objective on shares of Teladoc in a report on Friday, July 14th. Zacks Investment Research downgraded Teladoc from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. Chardan Capital raised their price target on Teladoc from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, May 9th. TheStreet downgraded Teladoc from a “c-” rating to a “d” rating in a research note on Monday, July 3rd. Finally, Robert W. Baird restated an “outperform” rating and issued a $33.00 price target (up from $28.00) on shares of Teladoc in a research note on Friday, June 16th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $32.77.
In other Teladoc news, CEO Jason N. Gorevic sold 19,991 shares of the business’s stock in a transaction on Tuesday, June 6th. The shares were sold at an average price of $32.89, for a total value of $657,503.99. Following the sale, the chief executive officer now owns 831,650 shares in the company, valued at approximately $27,352,968.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Jason N. Gorevic sold 13,389 shares of the business’s stock in a transaction on Monday, June 5th. The stock was sold at an average price of $32.89, for a total transaction of $440,364.21. Following the completion of the sale, the chief executive officer now owns 831,650 shares in the company, valued at approximately $27,352,968.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 168,380 shares of company stock valued at $4,805,918. 5.94% of the stock is currently owned by insiders.
Teladoc Company Profile
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with our FREE daily email newsletter.